- General info
- Available languages
- Background story
ITC Kloegirl™ font family
Designed by Scott Carslake
Up to 1 Family / 1 Value Packs
Supports at least 21 languages (Std / OT CFF)
Available licenses for all styles:
Supports up to 50 languages.
Please select a format to view the available languages:
Supports up to 7 OpenType features.
Please select a format to view the available OpenType features:
Most people have one recognizable style of handwriting; Australian fashion designer Chloé Papazahariakis has many. She changes the way she writes depending on her mood, where she is and what she’s working on. Her handwriting in a letter to a friend is quite different from the style she uses to add an entry to her personal diary.
“Carslake started collecting examples of Papazahariakis’s writing so that he could study the many different moods and personalities her handwriting was able to express. She even provided her personal diary as a design resource.
Carslake’s careful study resulted in Kloegirl Lotus and Kloegirl New York, named after Papazahariakis’s line of fashions.
Kloegirl Lotus is an all-lowercase typeface with a series of alternate characters in cap positions. Numerals maintain the same rhythm as the lowercase glyphs. Lotus’s many intriguing qualities include the fluid shapes and looping flourishes of the letterforms, especially in the descenders.
New York is a more traditional typeface with both caps and lowercase letters. The varying descenders are distinctive, but where Lotus’s curves and flourishes are soft and amiable, New York is an aggressive, sharp and opinionated design. For those times when the tone required is “friendly, but with an attitude,” characters from both faces can be used together.
Download a printable sample of ITC Kloegirl as a PDF.
Download a free trial
Use this font in your own documents with a free 5 minute trial through SkyFonts. Trials are for evaluation purposes only. Learn more.
This font is currently not available.
You already tried this font within the last 24 hours or you may have exceeded your daily allowance of trials. Learn more.